In:
Immunotherapy, Future Medicine Ltd, Vol. 11, No. 13 ( 2019-09), p. 1129-1147
Abstract:
A wide array of therapeutic strategies has been implemented against cancers, yet their clinical benefit is limited. The lack of clinical efficacy of the conventional treatment options might be due to the inept immune competency of the patients. Dendritic cells (DCs) have a vital role in initiating and directing immune responses and have been frequently used as delivery vehicles in clinical research. The recent clinical data suggest the potential use of DCs pulsed with nucleic acid, especially with RNA holds a great potential as an immunotherapeutic measure with compare to other cancer therapeutics. This review mainly deals with the DCs and their role in transfection with RNA in cancer immunotherapy.
Type of Medium:
Online Resource
ISSN:
1750-743X
,
1750-7448
DOI:
10.2217/imt-2019-0058
Language:
English
Publisher:
Future Medicine Ltd
Publication Date:
2019
Permalink